CELU (Celularity) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CELU Celularity Inc CELU
38 GF Score
Price $1.41
GF Value $2.44
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Celularity Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

CELU
38GF Score
Celularity Inc CELU
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celularity (CELU) Overvalued in 2026?

Based on GuruFocus' analysis, Celularity stock appears to be undervalued. The current stock price of $1.41 is trading 42.2% below its estimated GF Value™ of $2.44. GuruFocus considers Celularity to be Possible Value Trap.

Key valuation signals for CELU:

  • Dividend-Payout-to-FFO:
  • GF Value™: $2.44 vs. price of $1.41 (42.2% below fair value)
  • GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the CELU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celularity Business Description

Address 170 Park Avenue, Florham Park, NJ, USA, 07932
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
38GF Score

Get the complete analysis for CELU

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.41
Price
$2.44
GF Value